The PROSPECT II study was published in the March 13th issue of The Lancet,
finding that IVUS+NIRS imaging can detect plaques at increased risk for future adverse cardiac outcomes.VIEW ARTICLE VIEW ARTICLE

The Lipid-Rich Plaque Study Overview

Assessment of Coronary Near Infrared Spectroscopy Imaging to Detect Vulnerable Patients and Vulnerable Plaques

Ron Waksman, MD
Principal Investigator, LRP Study
MedStar Washington Hospital Center

We still see many patients that come to the cath lab for one event and have a subsequent event despite being treated with medical therapy. Some of these patients are optimally treated and still have events. The unmet need was to find an imaging technology able to detect vulnerable patients and vulnerable plaques. Doing that could be a good predictor for subsequent coronary events.

Study Summary

The landmark Lipid-Rich Plaque (LRP) study was designed to demonstrate that intravascular NIRS imaging can identify patients and plaques at risk for subsequent non-culprit major adverse cardiovascular events (NC-MACE) during a 24-month period. The results were presented by Dr. Ron Waksman and published in The Lancet on September 27, 2019.

The study successfully met both its co-primary endpoints as well as its key secondary endpoints, providing clinical evidence that intravascular NIRS imaging can accurately identify both vulnerable patients and vulnerable plaques that are at significantly higher risk for subsequent NC-MACE.

Learn more

Study Co-Primary Endpoints

Vulnerable Patient:

Association between maxLCBI4mm in all imaged arteries and future patient-level nonculprit MACE*

Vulnerable Plaque:

Association between maxLCBI4mm in a segment and incidence of future NC-MACE* in same segment

Study Secondary Endpoints

Vulnerable Patient:

A threshold of maxLCBI4mm>400 will identify patients and plaques at increased risk of a NC-MACE*

*Non-culprit MACE (independently adjudicated by CEC blinded to NIRS)

Key Findings

Vulnerable Patient Risk of NC-MACE

Firmly established that LCBI correlates to MACE risk and should be managed.

Vulnerable Plaque Risk of NC-MACE

Firmly established that LCBI correlates to MACE risk and should be managed


increased risk

for patients with overall maxLCBI4mm>400


increased risk

for each 100 unit increase in overall maxLCBI4mm


increased risk

for each 30mm Ware segment with maxLCBI4mm>400


increased risk

for each 100 unit increase in maxLCBI4mm for each Ware segment

Key findings as published in The Lancet on September 27, 2019

Example Case

The following example represents a typical case study of a patient enrolled in the LRP study and the subsequent observations of that patient.

A 44-year-old male with a past medical history of coronary artery disease, diabetes mellitus, hypertension and hyperlipidemia, presented with chest and right leg pain was imaged and scanned on April 30, 2014. The angiogram showed some non-obstructive plaque; the chemogram indicated that maxLCBI4mm was greater than 400, an indication of risk for subsequent NC-MACE. Twenty-two months later, the patient presented with unstable angina, which required percutaneous coronary intervention (PCI). New NIRS imaging showed that the new culprit lesion was located within the Ware segment previously identified on the chemogram.

LRP Case Study Example

Learn More

The Makoto™ Intravascular Imaging System is the only FDA-cleared imaging system indicated for the detection of plaque and patients at higher risk of MACE.

To request more information on how to obtain the Makoto™ system or its accompanying Dualpro™ IVUS+NIRS Catheter, or to see a demo, CLICK HERE

View the LRP Study in The Lancet

View Now

© 2020 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative